Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma
Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma
This was a retrospective, longitudinal, observational study conducted using the Flatiron Health electronic health record (EHR)-derived database. BRAF+ advanced or metastatic (i.e., stage III or IV) melanoma patients treated at oncology practices across the US were identified for potential inclusion. All included patients were aged ≥18 years and required to have a diagnosis of melanoma (International Classification of Diseases (ICD)-9 172.x & ICD-10 C43 or D03x), a pathologic unresectable stage III or IV diagnosis, subsequent first-line (1L) treatment with either immunotherapy (IO) (nivolumab, pembrolizumab, ipilimumab + nivolumab) or targeted therapy (TT) dafratenib + trametinib (dab/tram) on or after 01 January 2014, and evidence of a BRAF-positive result at any point in time.
Inclusion criteria:
Diagnosis of melanoma (ICD-9 172x & ICD-10 C43 or D03x)
≥2 documented clinical encounters on different days in the Flatiron network on or after 01 January 2011
Pathologic unresectable stage III or IV at initial diagnosis after 01 January 2011, or earlier stage disease accompanied by development of a first locoregional recurrence after 01 January 2011
Diagnosis of MM after 01 January 2011
Evidence of a BRAF-positive result at any point in time
Treatment with one of the following 1L therapies on or after 01 January 2014:
At least 18 years of age at the time of initiation of 1L therapy
At least 6-months of continuous follow-up from the time of initiation of 1L therapy
Exclusion Criteria: